Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

In the Spotlight

Tumor Antigen Heterogeneity: The “Elephant in the Room” of Adoptive T-cell Therapy for Solid Tumors

Steven M. Albelda
Steven M. Albelda
Department of Medicine, Division of Pulmonary, Allergy, and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: albelda@pennmedicine.upenn.edu
DOI: 10.1158/2326-6066.CIR-19-0801 Published January 2020
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

A major hurdle to the efficacy of adoptive cell therapy and chimeric antigen receptors T-cell therapy is the choice of antigen(s) to target. An article in this issue addresses this by capitalizing on the synergistic effect of pathogen-based immunotherapy and adoptive cell therapy that results in epitope/antigen spreading and enhancement of the endogenous T-cell response against antigens not originally targeted.

See article by Xin et al., p. 7

Adoptive transfer of T cells expressing chimeric antigen receptors (CAR) has revolutionized the treatment of many hematologic malignancies. Unfortunately, T-cell transfer for the treatment of solid tumors has not yet achieved similar success (1). One of the most important yet understudied challenges is the issue of tumor antigen heterogeneity (2), because not all tumor cells will express the targeted antigen, and even when present, the levels may be quite variable. In addition, therapy-induced immune editing could lead to antigen escape. Successful therapy will, thus, need to overcome this critical hurdle.

Tumor antigen heterogeneity could be overcome by the presence of “bystander effects,” the ability of the transferred T cells to also kill tumor cells that are not expressing the targeted antigen(s). This could occur by release of cytokines from the activated T cells or by engagement of death receptors on the nontargeted tumor cells. However, it is hoped that the most powerful bystander effects would be due to epitope (or antigen) spreading. In this process, transferred T cells kill targeted tumors cells, resulting in the release of tumor antigens in an immunostimulatory environment that are then taken up by antigen-presenting cells that have the ability to cross-present tumor antigens, ultimately generating endogenous B-cell and T-cell immunity against tumor antigens not originally targeted by the transferred T cells (3).

The extent of bystander killing that occurs after CAR or T-cell receptor (TCR) T-cell therapy has not been well studied. In this context, the study by Xin and colleagues in this issue (4), whose major goal was defining and augmenting epitope spreading, is timely and important. Using a syngeneic mouse model with defined tumor antigens, this group provide data that epitope spreading after treatment with T cells expressing a TCR targeted to the melanoma tumor antigen gp100 was minimal, resulting in the inability to eradicate tumor cells lacking gp100. However, by cotransducing the adoptively transferred T cells with a second TCR that recognizes a bacterially expressed antigen (ovalbumin) and treating tumors with modified Listeria bacteria that expresses ovalbumin, epitope spreading [mediated by BATF3+ dendritic cells (DC)] and bystander effects were markedly enhanced, along with the generation of central memory and tissue-resident memory CD8+ T cells. Although this study examined T cells transduced with TCRs and may have some issues relating to practicality and safety of intratumoral injections, it serves as an important proof of principle showing the importance of augmenting epitope spreading. Our group has similar data showing that CAR T cells are also very limited in the degree of epitope spreading that they induce without augmentation.

Finding a way to enhance bystander effects will be critical for success in treating most solid tumors where less than 100% of tumors express targeted antigens and in preventing immune editing–induced escape after therapy. Increasing epitope spreading is one strategy. This could include the approach described by Xin and colleagues in this issue (4) or DC activators delivered by the transferred T cells (i.e., IL12, flagellin, or CD40 ligand) or administered systemically (i.e., agonistic anti-CD40 antibody, FLT3 ligand, or STING agonists). Other potentially useful cargo could be cytokines or secreted bispecific T-cell engagers that would kill nonantigen-expressing cells. It may also be possible to address tumor heterogeneity by injecting mixtures of T cells that target multiple tumor antigens, transducing T cells with multiple CARs or TCRs targeting different antigens, or designing CARs that target multiple antigens.

Disclosure of Potential Conflicts of Interest

S.M. Albelda reports receiving commercial research grants from Novartis and Tmunity. No other potential conflicts of interest were disclosed.

Footnotes

  • Cancer Immunol Res 2020;8:2

  • ©2020 American Association for Cancer Research.

References

  1. 1.↵
    1. Newick K,
    2. O'Brien S,
    3. Moon E,
    4. Albelda SM
    . CAR T cell therapy for solid tumors. Annu Rev Med 2017;68:139–52.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Chen N,
    2. Li X,
    3. Chintala N,
    4. Tano Z,
    5. Adusumilli PS
    . Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr Opin Immunol 2018;51:103–30.
    OpenUrl
  3. 3.↵
    1. Sanchez-Paulete AR,
    2. Teijeira A,
    3. Cueto FJ,
    4. Garasa S,
    5. Perez-Garcia JL,
    6. Sanchez-Arraez A,
    7. et al.
    Antigen cross-presentation and T cell cross-priming in cancer immunology and immunotherapy. Ann Oncol 2017;28(suppl 12):xii44–xii55.
    OpenUrl
  4. 4.↵
    1. Xin G,
    2. Khatun A,
    3. Topchyan P,
    4. Zander R,
    5. Volberding PJ,
    6. Chen Y,
    7. et al.
    Pathogen-boosted adoptive cell transfer therapy induces endogenous antitumor immunity through antigen spreading. Cancer Immunol Res 2020;8:7–18.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Cancer Immunology Research: 8 (1)
January 2020
Volume 8, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Tumor Antigen Heterogeneity: The “Elephant in the Room” of Adoptive T-cell Therapy for Solid Tumors
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tumor Antigen Heterogeneity: The “Elephant in the Room” of Adoptive T-cell Therapy for Solid Tumors
Steven M. Albelda
Cancer Immunol Res January 1 2020 (8) (1) 2; DOI: 10.1158/2326-6066.CIR-19-0801

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tumor Antigen Heterogeneity: The “Elephant in the Room” of Adoptive T-cell Therapy for Solid Tumors
Steven M. Albelda
Cancer Immunol Res January 1 2020 (8) (1) 2; DOI: 10.1158/2326-6066.CIR-19-0801
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • Footnotes
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • How to Reprogram Myeloma-Associated Macrophages: Target IKZF1
  • Mystery Checkpoint Revealed: KIR3DL3 Finally Found a Ligand in HHLA2
  • TGFβ: Protecting PD-1 from mRNA Decay
Show more In the Spotlight
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement